Roche: agreement to acquire Telavant
(CercleFinance.com) - Roche announces that it has entered into a definitive agreement to acquire Telavant, a subsidiary of Roivant, including the rights to RVT-3101, Roivant's novel antibody to treat inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.
The Swiss healthcare group will obtain the rights to develop, manufacture and market RVT-3101 in the USA and Japan for the treatment of inflammatory bowel diseases and potentially multiple other diseases.
Roche will initially pay $7.1bn and a milestone payment of $150m soon. Subject to customary conditions, the transaction is expected to close in Q4 2023 or Q1 2024.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The Swiss healthcare group will obtain the rights to develop, manufacture and market RVT-3101 in the USA and Japan for the treatment of inflammatory bowel diseases and potentially multiple other diseases.
Roche will initially pay $7.1bn and a milestone payment of $150m soon. Subject to customary conditions, the transaction is expected to close in Q4 2023 or Q1 2024.
Copyright (c) 2023 CercleFinance.com. All rights reserved.